39.87 USD
+1.59 (+4.15%)
40.15 USD
+0.28 (+0.7%)
Taking everything into account, PAHC scores 7 out of 10 in our fundamental rating. PAHC was compared to 191 industry peers in the Pharmaceuticals industry. PAHC scores excellent on profitability, but there are some minor concerns on its financial health. PAHC may be a bit undervalued, certainly considering the very reasonable score on growth Finally PAHC also has an excellent dividend rating. With these ratings, PAHC could be worth investigating further for value and dividend investing!.
1. Profitability
1.1 Basic Checks
PAHC had positive earnings in the past year.
PAHC had a positive operating cash flow in the past year.
In the past 5 years PAHC has always been profitable.
In the past 5 years PAHC always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.89%, PAHC belongs to the top of the industry, outperforming 86.39% of the companies in the same industry.
PAHC has a Return On Equity of 21.76%. This is amongst the best in the industry. PAHC outperforms 92.15% of its industry peers.
PAHC has a Return On Invested Capital of 11.94%. This is amongst the best in the industry. PAHC outperforms 91.10% of its industry peers.
PAHC had an Average Return On Invested Capital over the past 3 years of 8.29%. This is below the industry average of 12.85%.
The last Return On Invested Capital (11.94%) for PAHC is above the 3 year average (8.29%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.89% | ||
| ROE | 21.76% | ||
| ROIC | 11.94% |
ROA(3y)2.38%
ROA(5y)3.78%
ROE(3y)9.79%
ROE(5y)14.19%
ROIC(3y)8.29%
ROIC(5y)8.41%
1.3 Margins
PAHC has a better Profit Margin (4.85%) than 81.68% of its industry peers.
PAHC's Profit Margin has declined in the last couple of years.
PAHC's Operating Margin of 12.04% is amongst the best of the industry. PAHC outperforms 84.82% of its industry peers.
In the last couple of years the Operating Margin of PAHC has grown nicely.
PAHC has a Gross Margin of 31.92%. This is comparable to the rest of the industry: PAHC outperforms 57.07% of its industry peers.
PAHC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.04% | ||
| PM (TTM) | 4.85% | ||
| GM | 31.92% |
OM growth 3Y8.12%
OM growth 5Y4.74%
PM growth 3Y-10.66%
PM growth 5Y-2.37%
GM growth 3Y1.41%
GM growth 5Y-0.32%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PAHC is creating some value.
The number of shares outstanding for PAHC remains at a similar level compared to 1 year ago.
Compared to 5 years ago, PAHC has about the same amount of shares outstanding.
Compared to 1 year ago, PAHC has a worse debt to assets ratio.
2.2 Solvency
PAHC has an Altman-Z score of 3.07. This indicates that PAHC is financially healthy and has little risk of bankruptcy at the moment.
PAHC has a Altman-Z score of 3.07. This is in the better half of the industry: PAHC outperforms 67.02% of its industry peers.
PAHC has a debt to FCF ratio of 21.67. This is a negative value and a sign of low solvency as PAHC would need 21.67 years to pay back of all of its debts.
PAHC's Debt to FCF ratio of 21.67 is fine compared to the rest of the industry. PAHC outperforms 74.87% of its industry peers.
PAHC has a Debt/Equity ratio of 2.32. This is a high value indicating a heavy dependency on external financing.
PAHC has a worse Debt to Equity ratio (2.32) than 78.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.32 | ||
| Debt/FCF | 21.67 | ||
| Altman-Z | 3.07 |
ROIC/WACC1.33
WACC8.95%
2.3 Liquidity
A Current Ratio of 3.09 indicates that PAHC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.09, PAHC is in line with its industry, outperforming 52.88% of the companies in the same industry.
A Quick Ratio of 1.35 indicates that PAHC should not have too much problems paying its short term obligations.
The Quick ratio of PAHC (1.35) is worse than 67.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.09 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
PAHC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.43%, which is quite impressive.
The Earnings Per Share has been growing by 14.12% on average over the past years. This is quite good.
Looking at the last year, PAHC shows a very strong growth in Revenue. The Revenue has grown by 33.71%.
Measured over the past years, PAHC shows a quite strong growth in Revenue. The Revenue has been growing by 10.12% on average per year.
EPS 1Y (TTM)76.43%
EPS 3Y19.98%
EPS 5Y14.12%
EPS Q2Q%108.57%
Revenue 1Y (TTM)33.71%
Revenue growth 3Y11.21%
Revenue growth 5Y10.12%
Sales Q2Q%39.74%
3.2 Future
PAHC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.77% yearly.
PAHC is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -2.45% yearly.
EPS Next Y33.72%
EPS Next 2Y21.35%
EPS Next 3Y17.77%
EPS Next 5YN/A
Revenue Next Year14.65%
Revenue Next 2Y8.81%
Revenue Next 3Y6.86%
Revenue Next 5Y-2.45%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.14, the valuation of PAHC can be described as correct.
Based on the Price/Earnings ratio, PAHC is valued cheaply inside the industry as 85.34% of the companies are valued more expensively.
PAHC's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.59.
Based on the Price/Forward Earnings ratio of 12.95, the valuation of PAHC can be described as correct.
Based on the Price/Forward Earnings ratio, PAHC is valued cheaply inside the industry as 83.77% of the companies are valued more expensively.
PAHC is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.80, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.14 | ||
| Fwd PE | 12.95 |
4.2 Price Multiples
87.43% of the companies in the same industry are more expensive than PAHC, based on the Enterprise Value to EBITDA ratio.
PAHC's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. PAHC is cheaper than 78.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.13 | ||
| EV/EBITDA | 10.08 |
4.3 Compensation for Growth
PAHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PAHC has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as PAHC's earnings are expected to grow with 17.77% in the coming years.
PEG (NY)0.48
PEG (5Y)1.14
EPS Next 2Y21.35%
EPS Next 3Y17.77%
5. Dividend
5.1 Amount
PAHC has a Yearly Dividend Yield of 1.18%.
PAHC's Dividend Yield is rather good when compared to the industry average which is at 6.46. PAHC pays more dividend than 91.10% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.31, PAHC's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.18% |
5.2 History
The dividend of PAHC has a limited annual growth rate of 0.02%.
PAHC has paid a dividend for at least 10 years, which is a reliable track record.
PAHC has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)0.02%
Div Incr Years0
Div Non Decr Years10
5.3 Sustainability
PAHC pays out 28.68% of its income as dividend. This is a sustainable payout ratio.
The dividend of PAHC is growing, but earnings are growing more, so the dividend growth is sustainable.
DP28.68%
EPS Next 2Y21.35%
EPS Next 3Y17.77%
39.87
+1.59 (+4.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners99.37%
Inst Owner Change-2.91%
Ins Owners0.52%
Ins Owner Change31.32%
Market Cap1.62B
Revenue(TTM)1.40B
Net Income(TTM)67.82M
Analysts48.89
Price Target43.86 (10.01%)
Short Float %4.53%
Short Ratio3.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.18% |
Yearly Dividend0.48
Dividend Growth(5Y)0.02%
DP28.68%
Div Incr Years0
Div Non Decr Years10
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.22%
Min EPS beat(2)7.47%
Max EPS beat(2)14.97%
EPS beat(4)4
Avg EPS beat(4)16.45%
Min EPS beat(4)7.47%
Max EPS beat(4)24.57%
EPS beat(8)8
Avg EPS beat(8)18.22%
EPS beat(12)9
Avg EPS beat(12)8.1%
EPS beat(16)10
Avg EPS beat(16)2.75%
Revenue beat(2)2
Avg Revenue beat(2)2.66%
Min Revenue beat(2)2.5%
Max Revenue beat(2)2.82%
Revenue beat(4)2
Avg Revenue beat(4)0.47%
Min Revenue beat(4)-3.24%
Max Revenue beat(4)2.82%
Revenue beat(8)6
Avg Revenue beat(8)1.31%
Revenue beat(12)6
Avg Revenue beat(12)-0.12%
Revenue beat(16)10
Avg Revenue beat(16)0.58%
PT rev (1m)31.63%
PT rev (3m)51.76%
EPS NQ rev (1m)-1.83%
EPS NQ rev (3m)4.69%
EPS NY rev (1m)4.08%
EPS NY rev (3m)18.1%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)-0.9%
Revenue NY rev (1m)0.47%
Revenue NY rev (3m)1.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.14 | ||
| Fwd PE | 12.95 | ||
| P/S | 1.15 | ||
| P/FCF | 47.13 | ||
| P/OCF | 21.04 | ||
| P/B | 5.18 | ||
| P/tB | 7.45 | ||
| EV/EBITDA | 10.08 |
EPS(TTM)2.47
EY6.2%
EPS(NY)3.08
Fwd EY7.72%
FCF(TTM)0.85
FCFY2.12%
OCF(TTM)1.89
OCFY4.75%
SpS34.53
BVpS7.69
TBVpS5.35
PEG (NY)0.48
PEG (5Y)1.14
Graham Number20.67
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.89% | ||
| ROE | 21.76% | ||
| ROCE | 15.11% | ||
| ROIC | 11.94% | ||
| ROICexc | 12.92% | ||
| ROICexgc | 14.23% | ||
| OM | 12.04% | ||
| PM (TTM) | 4.85% | ||
| GM | 31.92% | ||
| FCFM | 2.45% |
ROA(3y)2.38%
ROA(5y)3.78%
ROE(3y)9.79%
ROE(5y)14.19%
ROIC(3y)8.29%
ROIC(5y)8.41%
ROICexc(3y)9.26%
ROICexc(5y)9.5%
ROICexgc(3y)10.65%
ROICexgc(5y)11.26%
ROCE(3y)10.49%
ROCE(5y)10.64%
ROICexgc growth 3Y1.17%
ROICexgc growth 5Y-1.23%
ROICexc growth 3Y4.48%
ROICexc growth 5Y1.99%
OM growth 3Y8.12%
OM growth 5Y4.74%
PM growth 3Y-10.66%
PM growth 5Y-2.37%
GM growth 3Y1.41%
GM growth 5Y-0.32%
F-Score5
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.32 | ||
| Debt/FCF | 21.67 | ||
| Debt/EBITDA | 3.32 | ||
| Cap/Depr | 86.01% | ||
| Cap/Sales | 3.04% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 35.24% | ||
| Profit Quality | 50.56% | ||
| Current Ratio | 3.09 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 3.07 |
F-Score5
WACC8.95%
ROIC/WACC1.33
Cap/Depr(3y)116.74%
Cap/Depr(5y)111.08%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.43%
EPS 3Y19.98%
EPS 5Y14.12%
EPS Q2Q%108.57%
EPS Next Y33.72%
EPS Next 2Y21.35%
EPS Next 3Y17.77%
EPS Next 5YN/A
Revenue 1Y (TTM)33.71%
Revenue growth 3Y11.21%
Revenue growth 5Y10.12%
Sales Q2Q%39.74%
Revenue Next Year14.65%
Revenue Next 2Y8.81%
Revenue Next 3Y6.86%
Revenue Next 5Y-2.45%
EBIT growth 1Y95.15%
EBIT growth 3Y20.25%
EBIT growth 5Y15.34%
EBIT Next Year75.33%
EBIT Next 3Y25.44%
EBIT Next 5Y2.18%
FCF growth 1Y732.23%
FCF growth 3YN/A
FCF growth 5Y10.58%
OCF growth 1Y91.01%
OCF growth 3Y36.29%
OCF growth 5Y6.19%
PHIBRO ANIMAL HEALTH CORP-A / PAHC FAQ
Can you provide the ChartMill fundamental rating for PHIBRO ANIMAL HEALTH CORP-A?
ChartMill assigns a fundamental rating of 7 / 10 to PAHC.
Can you provide the valuation status for PHIBRO ANIMAL HEALTH CORP-A?
ChartMill assigns a valuation rating of 7 / 10 to PHIBRO ANIMAL HEALTH CORP-A (PAHC). This can be considered as Undervalued.
What is the profitability of PAHC stock?
PHIBRO ANIMAL HEALTH CORP-A (PAHC) has a profitability rating of 8 / 10.
How financially healthy is PHIBRO ANIMAL HEALTH CORP-A?
The financial health rating of PHIBRO ANIMAL HEALTH CORP-A (PAHC) is 5 / 10.
Can you provide the expected EPS growth for PAHC stock?
The Earnings per Share (EPS) of PHIBRO ANIMAL HEALTH CORP-A (PAHC) is expected to grow by 33.72% in the next year.